Multiple myeloma

We recently reported results in 54 multiple myeloma patients who first received a cytoreductive autologous HCT followed by a planned nonmyeloablative HCT.64 Patients were 29-71 (median 52) years old and had previously treated stage II or III multiple myeloma. Forty-eight percent had refractory (35%) or relapsed (13%) disease. Conditioning regimens for autologous and nonmyeloablative transplants were melphalan 200 mg/m2 and 2 Gy TBI, respectively. Nonmyeloablative HCT was performed 40-229 (median 62) days after the autologous transplant. The 100-day mortalities after autologous and allogeneic HCT were 2 and 2%, respectively. With a median follow-up of 552 days after allografting, 57% of patients achieved complete remissions and 26% partial remissions. Of the 28 patients with responsive disease entering the trial (complete/partial remissions), 3 have died and 2 have had disease progression. In contrast, of the 26 patients with relapsed or refractory disease at study entry, 9 have died. Causes of death in both groups were complications related to GvHD (n = 4), progression (n = 3), pulmonary failure (n = 2), lung cancer (n = 1), CMV infection (n = 1), and encephalopathy (n = 1). The estimated 2-year overall and progression-free survivals were 78 and 55%, respectively.

Smoking Solutions

Smoking Solutions

How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution. Get All The Support And Guidance You Need To Be A Success At Quitting Smoking. This Book Is One Of The Most Valuable Resources In The World When It Comes To How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution.

Get My Free Ebook


Post a comment